Evidence map›Paper›PMID 33770398›Full record

ReviewInfectious diseases and therapy2021

Clostridium difficile: Diagnosis and the Consequence of Over Diagnosis.

Helen S Lee, Kamryn Plechot, Shruti Gohil, Jennifer Le

Open access · goldAbstract readReview
In one paragraph

Review in Infectious diseases and therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.

  1. The value of fecal calprotectin inFrontiers in physiology · 2022
    Pooled it
  2. Clostridioides difficile Near-Patient Testing Versus Centralized Testing: A Pragmatic Cluster Randomized Crossover Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Trial
  3. Article
  4. Article
  5. Molecular epidemiology ofMicrobiology spectrum · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Practice Variations in the Management ofGastro hep advances · 2026
    Article
  11. Challenges and Strategies in Managing RecurrentGeriatrics (Basel, Switzerland) · 2025
    Article
  12. Peptidoglycan LD-Transpeptidases.Antibiotics (Basel, Switzerland) · 2025
    Review
  13. Global burden and trends of theAnnals of medicine · 2025
    Observational
  14. Article
  15. Lipidomics, Microbiota, and IntestinalInternational journal of molecular sciences · 2025
    Review
  16. Review
  17. Review
  18. Comprehensive review ofWorld journal of gastrointestinal pharmacology and therapeutics · 2025
    Article
  19. Predicting positiveHeliyon · 2025
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Helen S LeeDepartment of Pharmacy, University of California Irvine Health, Orange, CA, USA. ansh@hs.uci.edu.ORCID http://orcid.org/0000-0002-0229-2479
Kamryn PlechotDepartment of Pharmacy, University of California Irvine Health, Orange, CA, USA.
Shruti GohilDepartment of Medicine, Division of Infectious Diseases, University of California Irvine, School of Medicine, Irvine, CA, USA.
Jennifer LeSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, USA.
University of California, Irvine · USUniversity of California San Diego · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clostridium difficile infection (CDI) is a leading cause of healthcare-associated infections, accounting for significant disease burden and mortality. The clinical spectrum of C. difficile ranges from asymptomatic colonization to toxic megacolon and fulminant colitis. CDI is characterized by new onset of ≥ 3 unformed stools in 24 h and is confirmed by laboratory test for the presence of toxigenic C. difficile. Currently, laboratory tests to diagnose CDI include toxigenic culture, glutamate dehydrogenase (GDH), nucleic acid amplification test (NAAT), and toxins A/B enzyme immunoassay (EIA). The sensitivities of these tests are variable with toxin EIA ranging from 53 to 60% and with NAAT at about 95%. Overall, the specificity is > 90% for these methods. However, the positive predictive value (PPV) depends on the disease prevalence with lower CDI rates associated with lower PPVs.Notably, the widespread use of the highly sensitive NAAT and its relatively lower clinical specificity have led to overdiagnosis of C. difficile by identifying carriers when NAAT is used as the sole diagnostic method. Overdiagnosis of C. difficile has resulted in unwarranted treatment, possibly attributing to resistance to metronidazole and vancomycin, increased risk for overgrowth of vancomycin-resistant enterococci strains in stool specimens, and increased hospitalization thereby impacting patient safety and healthcare costs.Strategies to optimize the clinical sensitivity and specificity of current laboratory tests are critical to differentiate the clinical CDI from colonization. To achieve high diagnostic yield, if preagreed institutional criteria for stool submission are not used, a multistep approach to CDI diagnosis is recommended, such as either GDH or NAAT followed by toxins A/B EIA in conjunction with laboratory stewardship by evaluating C. difficile test orders for appropriateness and providing feedback. Furthermore, antimicrobial stewardship, along with provider education on appropriate testing for C. difficile, is vital to differentiate CDI from colonization.

Indexed as

Antimicrobial stewardshipC. difficileC. difficile colonizationC. difficile diagnostic predictive valuesC. difficile diagnostic sensitivity and specificityC. difficile infectionC. difficile NAATDiagnosisDiagnostic stewardshipOver diagnosis

Identifiers

PMID33770398
PMCPMC8116462
OpenAlexW3139474443

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.